In this review we describe an international project, conducted by the Paediatric Rheumatology International Trials Organization (PRINTO) that was aimed to identify, validate and promulgate core sets of measures and a definition of improvement for the evaluation of response to therapy in clinical trials and in daily clinical practice in patients with juvenile systemic lupus erythematosus (JSLE).
The following clinical measures were included in the PRINTO core set of outcome measure for the evaluation of response to therapy: 1) physician's global assessment of disease activity; 2) global disease activity measure; 3) 24-hour proteinuria; 4) parent's global assessment of the overall patient's well-being; 5) health-related quality of life assessment. The measures included in the core set were found to be feasible and not redundant, to have good construct validity, discriminative ability, internal consistency, with fair responsiveness to clinically important change in disease activity, and to be associated strongly with treatment outcome.
In order to be classified as responder to a given treatment, a patient should demonstrate at least 50% improvement from baseline in any two of the five core set measures with no more than one of the remaining worsening by more than 30%. This definition is now known as the `PRINTO/American College of Rheumatology (ACR) provisional criteria for JSLE'.
The proposed core set and definition of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in JSLE. The definition is now proposed for use in JSLE clinical trials, and may help physicians to decide if a child with SLE has responded adequately to therapy. Lupus (2007) 16, 670—676.
Flanc RS, Roberts MA, Strippoli Gfm, Chadban SJ, Kerr PG, Atkins RCTreatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis2004; 43: 197—208.
2.
Contreras G. , Pardo V., Leclercq B. et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med2004; 350: 971—980.
3.
Strand V., Gladman D., Isenberg D., Petri M., Smolen J., Tugwell P.Outcome measures to be used in clinical trials in systemic lupus erythematosus . J Rheumatol1999; 26: 490—497.
4.
Smolen JS, Strand V., Cardiel M., et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains. J Rheumatol1999; 26: 504—507.
5.
The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity . Arthritis Rheum2004; 50: 3418—3426.
6.
Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum2004; 50: 3427—3431.
7.
Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria.The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum2006; 54: 421—432.
8.
Tucker LB, Menon S., Schaller JG, Isenberg DAAdult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol1995; 34: 866—872.
9.
Font J., Cervera R., Espinosa G. et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis1998 ; 57: 456—459.
10.
Carreno L., Lopez-Longo FJ, Monteagudo I. et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus1999; 8: 287—292.
11.
Brunner HI, Silverman ED, To T., Bombardier C., Feldman BMRisk factors for damage in childhood-onset systemic lupus erythematosus — Cumulative disease activity and medication use predict disease damage. Arthritis Rheum2002; 46: 436—444.
12.
Ravelli A., Duarte-Salazar C., Buratti S. et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis RheumArthritis Care Res2003; 49: 501—507.
13.
Ruperto N., Martini A.International research networks in pediatric rheumatology: the PRINTO perspective . Curr Opin Rheumatol2004; 16: 566—570.
14.
Ruperto N., Ravelli A., Murray KJ et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis . Rheumatology (Oxford) 2003; 42: 1452—1459.
15.
Ruperto N., Ravelli A., Cuttica R. et al. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. Arthritis Rheum2005; 52: 2854—2864.
16.
Ruperto N., Ravelli A., Oliveira S. et al. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Prospective validation of the definition of improvement. Arthritis Rheum2006; 55: 355—363.
17.
Delbecq AL, Van de Ven AH, Gustafson DHGroup techniques for program planning. A guide to nominal group and Delphi processes, 1st edition. Scott, Foresman and Company, 1975.
Giannini EH , Ruperto N., Ravelli A., Lovell DJ, Felson DT, Martini A.Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum1997; 40: 1202—1209.
20.
Felson DT, Anderson JJ, Boers M. et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum1995 ; 38:727—735.
21.
Rider LG, Giannini EH, Harris-Love M. et al. Defining clinical improvement in adult and juvenile myositis . J Rheumatol2003; 30: 603—617.
22.
Rider LG, Giannini EH, Brunner HI et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum2004; 50: 2281—2290.
23.
Oddis CV, Rider LG, Reed AM et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum2005; 52: 2607—2615.
24.
Martini A., Ruperto N., Lovell DJ, Giannini EH, for the Paediatric Rheumatology International Trials Organisation (PRINTO), and for the Pediatric Rheumatology Collaborative Study Group (PRCSG).An international Consensus Conference to define core sets of outcome measures for juvenile systemic lupus erythematosus and juvenile dermatomyositis. Conference proceedings;Pavia, Italy, “Almo Collegio Borromeo”, 31 March—3 April 2001. PRINTO proceedings ; Pavia, Italy, IRCCS S. Matteo : Paediatric Rheumatology International Trials Organisation (PRINTO); 2001: p 1—134.
25.
Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271—1277.
26.
Hochberg MCUpdating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
27.
Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CHDerivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630—640.
28.
Liang MH, Socher SA, Larson MG, Schur PHReliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum1989; 32: 1107—1118.
29.
Vitali C., Bencivelli W., Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol1992; 10: 541—547.
30.
Vitali C., Bencivelli W., Mosca M., Carrai P., Sereni M., Bombardieri S.Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol1999; 26: 498—501.
31.
Landgraf JM, Abetz L., Ware JEThe CHQ user's manual, 1st edition. The Health Institute, New England Medical Center, 1996.
32.
Ruperto N., Ravelli A., Pistorio A. et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol2001; 19: S1—S9.
33.
Singh G., Athreya BH, Fries JF, Goldsmith DPMeasurement of health status in children with juvenile rheumatoid arthritis . Arthritis Rheum1994; 37: 1761—1769.
34.
Boers M., Brooks P., Strand CV, Tugwell P.The OMERACT filter for outcome measures in rheumatology. J Rheumatol1998; 25: 198—199.
35.
Bellamy N.Clinimetric concepts in outcome assessment: The OMERACT filter. J Rheumatol1999; 26: 948—950.
36.
Liang MH, Fossel AH, Larson MGComparisons of five health status instruments for orthopedic evaluation. Med Care1990; 28: 632—642.
37.
Cronbach LJCoefficient alfa and the internal structure of tests. Psychometrika1951; 16:297—334.
